Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Axitinib in Advanced Special Pathological Type Renal Cell Carcinoma
NCT05808608Phase 2Active, not recruiting
- Start
- Nov 2023
- Primary completion
- Apr 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in renal cell carcinoma (RCC). Started Nov 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05808608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808608.